Previous 10 | Next 10 |
BOSTON, MA / ACCESSWIRE / March 24, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) ,a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced tha...
Boston-based Pieris Pharmaceuticals ( NASDAQ: PIRS ) said it achieved a $5M milestone from Seagen after the Bothell, Wash.-based company dosed the first patient in a phase 1 trial of cancer drug SGN-BB228 (PRS-346). The Seagen-sponsored phase 1 study is evaluating the sa...
BOSTON, MA / ACCESSWIRE / January 10, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other conditions, today announ...
BOSTON, MA / ACCESSWIRE / November 23, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today annou...
BOSTON, MA / ACCESSWIRE / November 9, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announ...
Pieris Pharmaceuticals, Inc. (PIRS) Q3 2022 Earnings Conference Call November 02, 2022, 08:00 ET Company Participants Thomas Bures - SVP & CFO Stephen Yoder - CEO, President & Director Shane Olwill - SVP & Chief Development Officer Conference Ca...
The following slide deck was published by Pieris Pharmaceuticals, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Pieris Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation
Pieris Pharmaceuticals press release ( NASDAQ: PIRS ): Q3 GAAP EPS of -$0.13 in-line. Revenue of $5.37M (+32.6% Y/Y) beats by $0.86M . Cash, cash equivalents, and investments totaled $69.8 million for the quarter ended September 30, 2022, compared to a cash and cas...
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, NOVEMBER 2, 2022 AT 8:00 AM EDT Elarekibep (PRS-060/AZD1402) phase 2a study for asthma enrollment continues First subject dosed in PRS-220 phase 1 study for idiopathic pulmonary fibrosis (IPF) PRS-344/S095012 phase 1 s...
BOSTON, MA / ACCESSWIRE / November 1, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, tod...
News, Short Squeeze, Breakout and More Instantly...
Pieris Pharmaceuticals Inc. Company Name:
PIRS Stock Symbol:
NASDAQ Market:
Pieris Pharmaceuticals Inc. Website:
Bank of Georgia Group Plc (BDGSF) is expected to report for Q1 2024 iCad Inc. (ICAD) is expected to report for Q1 2024 Yasheng Group (HERB) is expected to report for Q1 2024 Bit Digital Inc. (BTBT) is expected to report $0.01 for Q1 2024 Estrella Immunopharma Inc. (ESLA) is expect...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
2024-04-23 09:02:03 ET Pieris Pharmaceuticals Inc (PIRS) announced stock split at a ratio of 1-for-80 on 2024-04-23 ... Full story available on KlickAnalytics.com